The Priority Review

Tag

PF-08653944

1 story

  1. Clinical trials

    Pfizer registers Phase 3 trial of PF-08653944 in Chinese adults with overweight or obesity

    The study plans to enroll an estimated 432 participants and compares berobenatide (PF-08653944) with placebo. It is scheduled to start on October 15, 2026, with primary completion expected on June 6, 2028.